Sierra Oncology
Developing Transformative Therapies for Rare Cancers
November 2021
SAFE HARBOR STATEMENT

Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “plan”, “predict”, “expect,” “estimate,” “anticipate,” “intend,” “goal,” “strategy,” “believe,” and similar expressions and variations thereof. Forward-looking statements may include statements regarding the Company’s business strategy, cash flows and funding status, potential growth opportunities, preclinical and clinical development activities, the timing and results of preclinical research, clinical trials and potential regulatory approval and commercialization of product candidates. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in documents the Company has filed with the SEC. These forward-looking statements speak only as of the date of this presentation and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Certain information contained in this presentation may be derived from information provided by industry sources. The Company believes such information is accurate and that the sources from which it has been obtained are reliable. However, the Company cannot guarantee the accuracy of, and has not independently verified, such information.

TRADEMARKS:
The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.
Momelotinib is the potential treatment of choice for myelofibrosis patients with anemia

- Profile has demonstrated anemia improvement, symptom and spleen control, without platelet decreases

~3 months from pivotal Phase 3 MOMENTUM data

- High probability of success trial; FDA approval and launch expected <18 months

~$3B addressable market* in anemic MF patients in the US

- ~15K prevalent patients with anemia in the US

Could become the cornerstone of future combinations in myelofibrosis

- Momelotinib + SRA515 combination will provide proof-of-concept
- Targeting patient subsets where the unmet medical need remains

Current market cap of ~$506M

- ~22M FD shares outstanding(1)
- ~$97.1M cash as of 9/30/21(2)

Source: Sierra Market Research

*Sierra estimates ~15k U.S. prevalent patients at $200k/patient/year

(1) Assuming treasury stock method to account for outstanding options and Series A warrants and $23 stock price. See slide 23 for details.

(2) Additional $12.6M raised off ATM subsequent to the close of the third quarter.
**Myelofibrosis (MF):** a bone marrow cancer
- Caused by constitutive activation of JAK-STAT signaling
- Inflammation and fibrosis impair red blood cell production

**Common manifestations** of disease include constitutional symptoms, enlarged spleen and **progressive anemia**

**Current treatments:** JAK inhibitors are the mainstay option for intermediate and high-risk patients
Importance of Treating Anemia in Myelofibrosis
Anemia and Hepcidin Predict Poor Survival in Myelofibrosis

Anemia of inflammation driven by elevated hepcidin

Elevated hepcidin inhibits iron transport and iron homeostasis

Anemia and elevated hepcidin are negative prognostic indicators

New therapies should provide anemia benefits in addition to symptom, spleen benefits

Anemia Predicts Poor Survival in Myelofibrosis*

- No anemia (Hb >12 g/dL)
  - Median survival 7.9 years
- Mild anemia (Hb 10–12 g/dL)
  - Median survival 4.9 years
- Moderate anemia (Hb 8–10 g/dL)
  - Median survival 3.4 years
- Severe anemia (Hb <6 g/dL)
  - Median survival 2.1 years

Hepcidin Predicts Poor Survival in Myelofibrosis**

- Low hepcidin
- High hepcidin


Momelotinib
A JAK1, JAK2 and ACVR1 (ALK2) Inhibitor
Momelotinib Inhibits JAK1, JAK2 and ACVR1/ALK2

Hyperactive JAK-STAT signaling is driving the disease in myelofibrosis

Preclinical and clinical studies suggest that the clinical anemia benefits of momelotinib result from suppression of ACVR1/ALK2-mediated hepcidin production

Momelotinib Inhibits all Three Disease Drivers, Potentially Improving Splenomegaly and Symptoms of Myelofibrosis While Maintaining or Improving Hemoglobin

Completed Phase 3 Studies SIMPLIFY-1 and -2

**SIMPLIFY-1**

**1st-Line Population**
JAK inhibitor naïve

- Double-blind, N=432
- Randomization 1:1
- Primary Endpoint
  - Day 1
  - Week 24
  - Year 7
- Double-blind treatment
- Open label
- LTFU

<table>
<thead>
<tr>
<th>JAKI-naïve</th>
<th>Momelotinib 200 mg QD</th>
<th>Ruxolitinib 20 mg BID</th>
</tr>
</thead>
</table>

**SIMPLIFY-2**

**2nd-Line Population**
Prior ruxolitinib complicated by hematologic toxicity

- Randomized treatment
- Extension
- LTFU
- Year 7
- Primary Endpoint
  - Day 1
  - Week 24
- RUX-exposed
- Open label, N=156
- Best available therapy
- 88.5% = RUX/RUX+

- **Momelotinib 200 mg QD**
- **Momelotinib 200 mg QD**
- **Ruxolitinib 20 mg BID**

*Met endpoint
Journal of Clinical Oncology, 2017 35(34):3844

The Lancet Haematology, 2018 5(2): 7
S-1 Highlighted MMB’s Unique Impact on Hemoglobin and Transfusions

Momelotinib Demonstrated an Increase in Hemoglobin and a Decreased Transfusion Requirement vs. Ruxolitinib
Transfusion Independence is Achieved for Anemic Patients and all Patients, Irrespective of Baseline Platelets or Transfusion Status

SIMPLIFY-1 Anemic Patients
W24 TI-Response by Baseline Hgb

SIMPLIFY-1
W24 TI-Response by Baseline PLT

SIMPLIFY-1
W24 TI-Response by Baseline Transfusion Status

The W24 TI-R Rate in S1 Was Higher in Patients Randomized to MMB vs RUX, Irrespective of the Degree of Baseline Anemia, or the Baseline PLT Count or Transfusion Status

Week 24 Transfusion Independence Response (TI-R): no RBC transfusion within ≥ 12 weeks immediately prior to Week 24, with Hgb ≥ 8 g/dL
Transfusion Dependent (TD): ≥4 units of RBCs or Hgb level, ≤ 8 g/dL in the 8 weeks prior to randomization
Transfusion Independent (TI): absence of RBC transfusions and no Hgb < 8 g/dL in the 12 weeks prior to randomization
Transfusion Requiring (TR): neither TD nor TI
Hgb = hemoglobin, MMB = momelotinib, Plts = platelets, RUX = ruxolitinib, TD = transfusion dependent, TI = transfusion independent, TR = transfusion requiring
Transfusion Independence (TI) with Momelotinib is Associated with Improved Overall Survival

Week 24 TI response = no RBC transfusion for ≥ 12 weeks immediately prior to Week 24, Hgb level ≥ 8 g/dL.

Mesa, R. et.al. European Hematology Association, June 2021, oral presentation S202; Virtual.

Achieving or Maintaining TI Predicted Better Survival in Patients Treated with Momelotinib – The Goal of Achieving TI Should Become an Important Driver of Treatment Decisions

Week 24 TI response = no RBC transfusion for ≥ 12 weeks immediately prior to Week 24, Hgb level ≥ 8 g/dL.

Mesa, R. et.al. European Hematology Association, June 2021, oral presentation S202; Virtual.
Comparative Efficacy MMB vs RUX/BAT in Anemic Patients

MMB’s anemia benefits are accompanied by similar splenic and symptomatic response rates in SIMPLIFY-1 and significantly better symptom control relative to BAT in SIMPLIFY-2.

Week 24 Response Rates

**SIMPLIFY-1: Patients with Hgb ≤ 12 g/dL at Baseline**

- Anemia (TI) Response: MMB 62%, RUX 37%
- Splenic Response: MMB 29%, RUX 29%
- Symptom (TSS) Response: MMB 30%, RUX 39%

**SIMPLIFY-2: Patients with Hgb ≤ 12 g/dL at Baseline**

- Anemia (TI) Response: MMB 41%, RUX/BAT 15%
- Splenic Response: MMB 15%, RUX/BAT 8%
- Symptom (TSS) Response: MMB 28%, RUX/BAT 4%
SIMPLIFY-1: JAK Inhibitor-naïve Patients

Potential for MMB to improve outcomes in JAK-naïve patients:

- Splenic control with MMB equivalent to that achieved with RUX (27% vs. 29%)
- Symptom benefit clinically comparable when measured longitudinally and as individual scores
- Higher rates of transfusion independence for MMB-treated patients
- Long overall survival: Medians of 53 months and not reached

Transfusion Requirement was ~half for MMB vs. RUX

Mixed-Effect Model Repeated Measure (MMRM) Based TSS Change from Baseline (70-point scale)

<table>
<thead>
<tr>
<th>ITT Population</th>
<th>Symptomatic Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>MMB Population</td>
<td>RUX Population</td>
</tr>
<tr>
<td>MMB Baseline</td>
<td>19.0</td>
</tr>
<tr>
<td>MMB Week 24</td>
<td>17.5</td>
</tr>
<tr>
<td>RUX Baseline</td>
<td>25.1</td>
</tr>
<tr>
<td>RUX Week 24</td>
<td>23.1</td>
</tr>
</tbody>
</table>

Baseline TSS, LS mean: MMB Baseline 19.0, RUX Baseline 17.5

Week 24 Change from Baseline, LS Mean: MMB Baseline 17.5, RUX Baseline 25.1

Difference from RUX in W24 Change from Baseline, LS Mean: 1.5

Hematologic data supports potential for MMB to improve outcomes in JAK-naïve patients:

- Transfusion Requirement was ~half for MMB vs. RUX
- Comparable Symptom Benefit for all 7 items within the TSS
In patients previously treated with a JAK inhibitor:

- **MMB maintains splenic control**
  - MMB provides some measure of **splenic shrinkage** in 35% of MMB treated patients at Week 24
  - The mean percent change in spleen volume at Week 24 was 0.2% in the MMB group

- **Higher rates of symptom response and transfusion independence** achieved for MMB-treated patients

- **Long overall survival observed** in this JAK inhibitor-exposed setting
  - Median of 37.5 and 34.3 months
Comparative Efficacy MMB vs RUX in Patients with Low Platelet Counts

MMB does not require dose adjustment based on platelet count. By retaining full dose intensity, efficacy is maintained with MMB in contrast to RUX in patients with low platelet counts.

**Week 24 Response Rates**

**SIMPLIFY-1: Patients with 50 - 150 x10⁹ platelets/L at Baseline**

- Anemia (TI) Response: MMB 62%, RUX 42%
- Splenic Response: MMB 23%, RUX 4%
- Symptom (TSS) Response: MMB 28%, RUX 33%

**SIMPLIFY-2: Patients with ≤150 x10⁹ platelets/L at Baseline**

- Anemia (TI) Response: MMB 45%, RUX/BAT 22%
- Splenic Response: MMB 6%, RUX/BAT 5%
- Symptom (TSS) Response: MMB 24%, RUX/BAT 3%

*Including patients with <50 x 10⁹ platelets / L*
Safety and Tolerability from the SIMPLIFY Phase 3 Trials

- Safety generally similar for momelotinib, ruxolitinib in the 24-week double-blind period
  - Anemia and thrombocytopenia were more common in the ruxolitinib arm
  - Nausea was more common with momelotinib, as was the early withdrawal rate in S-1
- Tolerability persists with extended treatment
  - No evidence of long-term cumulative toxicity observed
- Safety profile enables long duration of dosing
  - Several patients from early trials have now received >10 years of continuous momelotinib therapy
  - Many patients from SIMPLIFY-1 and -2 continue to receive momelotinib

### SIMPLIFY-1

<table>
<thead>
<tr>
<th>Frequent TEAEs¹ by PT</th>
<th>Randomized Treatment Period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MMB (N=214)</td>
</tr>
<tr>
<td>Pts with any TEAE, n (%)</td>
<td>198 (92.5%)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>39 (18.2%)</td>
</tr>
<tr>
<td>Anemia</td>
<td>31 (14.5%)</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>40 (18.7%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>34 (15.9%)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>31 (14.5%)</td>
</tr>
</tbody>
</table>

### S-1 Extended

<table>
<thead>
<tr>
<th>Most Frequent TEAEs¹ by PT</th>
<th>Extended duration MMB Final Safety Analysis (N=411)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pts with any TEAE, n (%)</td>
<td>397 (96.6%)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>99 (24.1%)</td>
</tr>
<tr>
<td>Anemia</td>
<td>93 (22.6%)</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>94 (22.9%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>85 (20.7%)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>84 (20.4%)</td>
</tr>
</tbody>
</table>

¹ TEAEs occurring in >20% pts in the “Overall exposed to MMB” population including the 214 subjects receiving blinded momelotinib and 197 additional subjects who received momelotinib after cross-over from ruxolitinib
Danazol was selected as an appropriate comparator given its use to ameliorate anemia in MF patients, as recommended by NCCN, ESMO guidelines.

2:1 randomization

Double-Blind Treatment

Momelotinib 200 mg daily + Placebo

Danazol* 600 mg daily + Placebo

Open Label/Crossover

Momelotinib 200 mg daily

Long Term Follow-up

21 day JAKi taper/washout

Subjects

N=180

Previously Treated with JAK inhibitor
Symptomatic (TSS ≥ 10) and Anemic (Hgb < 10 g/dL)

Day 1

Week 24

Primary Endpoint

• Total symptom score (TSS) response rate at Week 24

Secondary Endpoints

• Transfusion independence (TI) rate at Week 24
• Splenic response rate (SRR) at Week 24

• Early crossover to open label in the event of confirmed symptomatic splenic progression

Primary Endpoint

Enrollment complete with 195 patients
Momelotinib + SRA515 Combinations Could Expand the Myelofibrosis Opportunity

Myelofibrosis landscape is evolving with multiple combination studies ongoing

- BET inhibition has shown initial proof-of-concept with disease-modifying potential
- Unlike other BET inhibitors, SRA515 has a novel bivalent binding mode
  - A stronger connection on the cellular level leads to improved potency
- SRA515 has favorable PK, PD and safety profile when dosed as monotherapy and in combination

Clinical validation of MMB + BET combination

- SRA515 has synergistic preclinical efficacy in combination with diverse agents
  - Best-in-class potential
- As a non-myelosuppressive inhibitor of JAK1, JAK2, and ACVR1, MMB is an ideal combination partner for novel agents
- SRA515+MMB has the potential to improve outcomes in patients with MF

Momelotinib + SRA515 may provide the opportunity for longer and more durable responses for myelofibrosis patients
MMB + SRA515 May be the “Winning” Combination

✓ **SRA515 potentially the most potent BETi with selective target inhibition**
  - Novel bivalent binding mode; Allows for maintained dosing durability

✓ **MMB may be the best combination agent as only JAKi with anemia benefit in MF**
  - Novel JAK1, JAK2 and ACVR1/ALK2 MOA does not add to myelosuppression of BETi

✓ **Sierra wholly owns both compounds, allowing for data-driven development approach**

✓ **Distinct advantage of extensive MMB clinical experience with almost 1,000 MF patients dosed**

✓ **Can create intelligent development plan due to both internally- and externally-derived data sources**
Sierra Oncology Clinical Program

Sierra’s pipeline affords numerous combination opportunities, with SOC and with other investigational agents

<table>
<thead>
<tr>
<th>Program</th>
<th>Indication</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Registration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Momelotinib monotherapy</td>
<td>Myelofibrosis</td>
<td>Topline results expected February 2022</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Momelotinib + SRA515*</td>
<td>Myelofibrosis</td>
<td>Planned for H1 2022</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRA515 monotherapy and/or</td>
<td>Heme malignancies**</td>
<td>Finalizing Design</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRA515 + SRA737</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRA515 monotherapy and/or</td>
<td>Solid tumor in combo with</td>
<td>Finalizing Design</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRA515 + SRA737</td>
<td>SOC**</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRA737 + IO/gemcitabine</td>
<td>Solid tumors</td>
<td>Finalizing Design</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Formerly AZD5153

**Opportunities currently under consideration include co-operative trials
**SRRA Ownership and Capitalization**

SRRA ownership is highly concentrated with quality long-term shareholders – the top 10 own ~80% of common shares outstanding (1)

- Vivo Capital
- Longitude Capital
- Orbimed Advisors
- Rock Springs Capital
- Abingworth Management
- Adage Capital
- Frazier Healthcare Partners
- Gilead Sciences
- Ikarian Capital
- Caxton Associates

With conversion of warrants and options, fully diluted shares outstanding are ~22M resulting in a market cap of ~ $506M at a $23 stock price

<table>
<thead>
<tr>
<th>Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common shares outstanding (2)</td>
<td>15,055,040</td>
</tr>
<tr>
<td>Series A warrants for common stock (treasury stock method)</td>
<td>3,319,592</td>
</tr>
<tr>
<td>Series B warrants for common stock</td>
<td>2,524,732</td>
</tr>
<tr>
<td>Gilead warrants for common stock (treasury stock method)</td>
<td>309,034</td>
</tr>
<tr>
<td>Employee stock options (3)</td>
<td>812,671</td>
</tr>
<tr>
<td><strong>Total FD Shares Outstanding</strong></td>
<td>22,021,068</td>
</tr>
</tbody>
</table>

**Fully Diluted Market Cap** $ 506,484,566

(1) Source: public filings as of 11/5/21
(2) Source: public filings as of 11/5/21. Note that common shares outstanding will change as the ATM is used and this number should not be relied upon for investment decisions.
(3) Based on 4.8M options outstanding with a weighted average exercise price of $19.11 per 10-Q for the period ending 9/30/21. Calculation uses treasury stock method.
Sierra Oncology Overview

Momelotinib is the potential treatment of choice for myelofibrosis patients with anemia

- Profile has demonstrated anemia improvement, symptom and spleen control, without platelet decreases

~3 months from pivotal Phase 3 MOMENTUM data

- High probability of success trial; FDA approval and launch expected <18 months

~$3B addressable market* in anemic MF patients in the US

- ~15K prevalent patients with anemia in the US

Could become the cornerstone of future combinations in myelofibrosis

- Momelotinib + SRA515 combination will provide proof-of-concept
- Targeting patient subsets where the unmet medical need remains

Current market cap of ~$506M

- ~22M FD shares outstanding(1)
- ~$97.1M cash as of 9/30/21(2)

Source: Sierra Market Research

*Sierra estimates ~15k U.S. prevalent patients at $200k/patient/year

(1) Assuming treasury stock method to account for outstanding options and Series A warrants and $23 stock price. See slide 23 for details.
(2) Additional $12.6M raised off ATM subsequent to the close of the third quarter.